At 9.3% growth with a PEG of 2.6, this CF monopoly charges premium prices for transitioning from fast grower to stalwart.

A fast grower with 86.2% revenue concentration in one franchise trades at a reasonable PEG despite margins that tell two different stories.

What kind of company is this and what should we expect?

This framework classifies Vertex as a fast grower transitioning to stalwart territory. While the 9.3% revenue growth falls just short of the 10% stalwart threshold, the 40.3% operating margins and consistent earnings expansion keep it in fast grower classification for now.

Can you explain why this company grows in one sentence?

The growth story is crystal clear: "They sell the only effective treatment for cystic fibrosis." This framework appreciates the simplicity - no complex technology explanation needed. The 86.2% concentration in one franchise makes the story both easy to understand and concerning.

Are we paying a fair price for the growth?

Applying this lens shows a PEG above 2.0, suggesting investors are paying a significant premium for the growth. This framework would typically pass at this valuation unless the growth story is exceptional - which a monopoly position in CF treatments might justify.

Can this company survive trouble?

This framework sees a fortress balance sheet. With $1.2B net cash and generating $3.2B in annual free cash flow, Vertex could survive years without revenue. The minimal debt provides enormous flexibility for R&D investment or acquisitions.

Applying this framework reveals a fast grower with a simple story - they dominate cystic fibrosis treatment. The 40.3% operating margins and fortress balance sheet demonstrate quality, but a PEG above 2.0 suggests paying too much for slowing growth. This framework would wait for a better price or faster growth to justify current valuation. Is 86.2% revenue concentration in one product a moat or a risk?

This analysis applies Peter Lynch's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Peter Lynch. Educational purposes only. Not financial advice.